newsfilter
← Latest News
GlobeNewswire·

BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress

Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programsAnnounced publication in Cancer Discovery highlighting preclinical data demonstrating BBO-11818 is a potent and